Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B‐MuD) for the treatment of relapsed multiple myeloma-Reference-Cited by-同舟云学术

Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B‐MuD) for the treatment of relapsed multiple myeloma

Published:2012-12-08 Issue:2 Volume:88 Page:102-106
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol

Author:

Mangiacavalli Silvia¹,Pochintesta Lara¹,Pascutto Cristiana¹,Cocito Federica¹,Cazzola Mario¹,Corso Alessandro¹

Affiliation:

1. Division of HematologyFondazione IRCCS Policlinico San MatteoUniversity of PaviaPaviaItaly

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.23358

Reference36 articles.

1. Improved survival in multiple myeloma and the impact of novel therapies

2. Relapsed Multiple Myeloma

3. Evidence-Based Mini-Review: Treatment Options for Patients with Relapsed/Refractory Myeloma Previously Treated with Novel Agents and High-Dose Chemotherapy and Autologous Stem-Cell Transplantation

4. Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto‐SCT: A multicenter feasibility study;Musso M;Bone Marrow Transplant

5. Clinical and pharmacokinetic phase II study of fotemustine in refractory and relapsing multiple myeloma patients

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Calcium silicate/bortezomib combinatory therapy for multiple myeloma;Journal of Materials Chemistry B;2023

2. Bortezomib Eliminates Persistent Chlamydia trachomatis Infection through Rapid and Specific Host Cell Apoptosis;International Journal of Molecular Sciences;2022-07-04

3. Is more better? An analysis of toxicity and response outcomes from dose-finding clinical trials in cancer;BMC Cancer;2021-07-05

4. Dose-finding designs for trials of molecularly targeted agents and immunotherapies;Journal of Biopharmaceutical Statistics;2017-02-06

5. Peripheral neuropathy outcomes and efficacy of subcutaneous bortezomib when combined with thalidomide and dexamethasone in the treatment of multiple myeloma;Experimental and Therapeutic Medicine;2016-09-21